Cite
HARVARD Citation
Hong, D. et al. (n.d.). Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial. European journal of cancer. pp. S72-. [Online].